Traversa Therapeutics Gets $2M

La Jolla-based Traversa Therapeutics said late Monday morning that it has raised $2M in a Series A funding from the Tech Coast Angels, along with Mesa Verde Venture Partners and Morningside Group. Traversa is developing RNAi delivery technologies. According to Traversa, the lead investor on the deal was the San Diego Tech Coast Angels' Franois Ferre, who is currently co-CEO of Althea Technologies. Dan Wood of Mesa Verde and Roger Flugel of Sanderling are now observors on the firm's board. Traversa's technology was developed by Professor Steven F. Dowdy at the Howard Hughes Medical Institute and the University of California San Diego. More information »